8-K: ProMIS Neurosciences Regains Nasdaq Compliance

ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously disclosed deficiency matter.

Summary

• ProMIS Neurosciences Inc. received notification on December 12, 2025, that it has regained compliance with the Nasdaq Capital Market's $1.00 minimum bid price requirement (NASDAQ Listing Rule 5550(a)(2)).
• The matter regarding the bid price deficiency is now closed.
• The company had previously received a deficiency letter on January 8, 2025, due to its common stock trading below $1.00 for 30 consecutive business days.
• An initial 180-day compliance period was granted until July 2, 2025, followed by an additional 180-day grace period until December 29, 2025.
• Compliance was achieved as the closing bid price of the company's common shares was $1.00 or greater for 10 consecutive business days from November 28, 2025, to December 11, 2025.

Sentiment

Score: 8

Explanation: The resolution of a Nasdaq listing deficiency is a significant positive event, removing a major regulatory risk and ensuring continued access to public markets. This is a clear positive for the company and its shareholders.

Positives

• Regained compliance with Nasdaq's $1.00 minimum bid price requirement, removing the risk of delisting.
• The Nasdaq deficiency matter is now closed.
• The company met other continued listing requirements, including stockholders' equity.

Negatives

• Previously faced a deficiency for trading below $1.00, indicating past share price weakness.
• The need for a potential reverse stock split was considered to cure the deficiency, though not ultimately executed for this compliance.

Risks

• Risk of delisting from Nasdaq due to not meeting the minimum bid price requirement (now resolved for this specific instance).
• Future share price volatility could lead to similar compliance issues.

Future Outlook

The company has successfully resolved its Nasdaq minimum bid price deficiency, ensuring its continued listing on the Nasdaq Capital Market. This removes an immediate regulatory hurdle, allowing management to focus on its core business objectives.

Management Comments

• Neil Warma, Chief Executive Officer, signed the report.

Industry Context

Maintaining a listing on a major exchange like Nasdaq is crucial for biotechnology companies like ProMIS Neurosciences, as it provides access to capital markets and enhances visibility among institutional investors. Compliance issues can deter investment and impact liquidity.

Stakeholder Impact

• Shareholders: Positive impact as the risk of delisting is removed, preserving liquidity and investment visibility.
• Investors: Increased confidence due to regulatory compliance.

Key Dates

Recommendation

While regaining Nasdaq compliance is a significant positive, it primarily removes a downside risk rather than indicating fundamental operational improvements or new growth catalysts. The stock previously traded below $1.00, suggesting underlying challenges. Investors should hold to observe sustained operational performance and strategic developments beyond just listing compliance.

Keywords

ProMIS Neurosciences, PMN, Nasdaq, Listing Compliance, Minimum Bid Price, Stock Market, Biotechnology, Neuroscience